5.4K(top 5%)
articles
153.7K(top 4%)
citations
1,711(top 4%)
★★ articles
84(top 3%)
★★★ articles
3.3(top 10%)
Avg IF
165(top 3%)
H-Index
277(top 3%)
G-Index
811
journals

Most Cited Articles of Royal Marsden NHS Foundation Trust

TitleJournalYearCitations
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammographyCa-A Cancer Journal for Clinicians20071.8K
Integrative clinical genomics of advanced prostate cancerCell20151.8K
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology20161.7K
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine20151.3K
Renal cell carcinomaNature Reviews Disease Primers2017963
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Oncology, The2017913
The evolutionary history of lethal metastatic prostate cancerNature2015857
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)Gut2010843
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyLancet, The2019839
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsLancet Oncology, The2013804
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature2017796
Multiple newly identified loci associated with prostate cancer susceptibilityNature Genetics2008722
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenJournal of Clinical Oncology2008713
EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technologyUltraschall in Der Medizin2013709
International evaluation of an AI system for breast cancer screeningNature2020707
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trialLancet Oncology, The2018680
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyLancet, The2019674
Combinatorial drug therapy for cancer in the post-genomic eraNature Biotechnology2012670
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working groupEuropean Journal of Cancer2010665
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysesCancer2003660
Prostate cancerLancet, The2016645
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJournal of Clinical Oncology2019637
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialLancet, The2016630
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialLancet Oncology, The2016590
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trialLancet Oncology, The2016587